Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
AssigneeImmunomedics, Inc.
InventorsChien-Hsing Chang, David M. Goldenberg, Hans J. Hansen, Edmund A. Rossi
Life of this patent
Estimating the term…
Loading patent…
AssigneeImmunomedics, Inc.
InventorsChien-Hsing Chang, David M. Goldenberg, Hans J. Hansen, Edmund A. Rossi
Estimating the term…
Disclosed are methods and compositions of anti-B cell antibodies, preferably anti-CD22 antibodies, for diagnosis, prognosis and therapy of B-cell associated diseases, such as B-cell malignancies, autoimmune disease and immune dysfunction disease. Preferably, the antibodies induce trogocytosis of B-cell antigens, such as CD19, CD20, CD21, CD22, CD79b, CD44, CD62L, or β7-integrin. Trogocytosis may play a significant role in determining antibody efficacy, disease responsiveness and prognosis of therapeutic intervention and trogocytosis-dependent responses may be monitored by measuring the levels of trogocytosis of one or more B-cell surface antigens induced by the bispecific antibody.
A method of treating systemic lupus erythematosus (SLE) comprising administering to a human subject with SLE a bispecific anti-CD22×anti-CD20 antibody comprising (i) a first antibody, wherein the C-terminal end of each light chain of the first antibody is conjugated to an anchor domain (AD) moiety from an A-kinase anchoring protein (AKAP);
Dependencies are inferred from the claim text.